Search

Your search keyword '"Kamusheva, Maria"' showing total 230 results
Start Over Author "Kamusheva, Maria"
230 results on '"Kamusheva, Maria"'

2. Pan‐European survey on medication adherence management by healthcare professionals.

Author

Kamusheva, Maria, Aarnio, Emma, Qvarnström, Miriam, Hafez, Gaye, Mucherino, Sara, Potočnjak, Ines, Trečiokiene, Indre, Mihajlović, Jovan, Ekenberg, Marie, van Boven, Job F. M., and Leiva‐Fernandez, Francisca

Subjects
*MEDICAL personnel, *PATIENT compliance, *DIGITAL technology, *MEDICATION reconciliation, *PHARMACISTS
Abstract

Aims: While medication adherence (MA) is a key prerequisite for achieving optimal clinical and economic outcomes, nonadherence is highly prevalent. Assessing how healthcare professionals (HCPs) in Europe manage MA, focusing on measurement, reporting and interventions, is the subject of this study. Methods: A cross‐sectional study was conducted among 40 European countries and quantitative analysis was conducted via an online survey. The multi‐language online survey was created using Webropol 3.0 survey and reporting tool. Descriptive statistics and chi‐squared tests were applied. Results: In total, 2875 HCPs (pharmacists: 39.9%; physicians: 36.7%; nurses: 16.4%) from 37 European countries participated. The most used methods for MA assessment were direct communication with patients (86.4%) and referring to personal patient records (56.7%) (P < 0.0001). Physicians (74.9%) and nurses (58.8%) were more aware of problems related to MA in contrast to pharmacists (48.6%) (P < 0.001). Almost all HCPs (92.6%) indicated that MA‐enhancing interventions involved mainly direct communication with nonadherent patients (93.3%) and their caregivers (55.7%). Medication review and related optimization of therapy were mainly performed in Western European countries (46.8%). Technological solutions were ranked as one of the less applied approaches (10–15%) (P < 0.001). Conclusions: HCPs in all European regions recognize MA management as an integral element of overall patient‐centred care. More efforts are needed to ensure timely, adequate and relevant MA assessment, reporting and improvement and involvement of all HCPs, especially among pharmacists who were generally less aware of MA issues. Promotion and use of digital technological solutions should be the focus of current and future clinical practice to optimize MA management processes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Transferability of new methods for health technology assessment in the field of diabetes between early and late adopters' countries.

Author

Tachkov, Konstantin, Somolinos-Simón, Francisco, Tapia-Galisteo, Jose, Hernando, Maria Elena, García-Sáez, Gema, Dimitrova, Maria, Kamusheva, Maria, Mitkova, Zornitsa, Petyko, Zsuzsanna, Nemeth, Bertalan, Kalo, Zoltan, Tesar, Tomas, Paveliu, Marian-Sorin, Piniazhko, Oresta, Lipska, Iga, Turcu-Stiolica, Adina, Savova, Alexandra, Manova, Manoela, Hren, Rok, and Došenović Bonča, Petra

Abstract

This study aimed to investigate the transferability of novel artificial intelligence (AI) methods for prediction modelling of diabetes based on real-world data (RWD) between early and late adopters of emerging health technologies from the perspective of developers and health technology assessment (HTA) experts. A two-step approach was used. Developers of the new AI methods within HTx consortium completed a survey about the benefits, usability, barriers associated with implementing the new prediction models in routine HTA practices. Then, HTA experts from Central and Eastern European (CEE) countries participated in a focus group discussion. Developers generally expressed optimism regarding the transferability of the methods, while acknowledging potential disparities across CEE countries. Key benefits that were identified included enhanced understanding of diabetes, improved cost-effectiveness modelling, and refined patient stratification, all of which could contribute to clinical and reimbursement decisions across various jurisdictions. The focus group underscored the value of real-world data for diabetes prediction modelling, serving as a beneficial resource for both clinicians and HTA agencies. However, there was a recognized need to clarify the processes of integrating randomized clinical trial data with real-world data. For the other stakeholders, the advancement of the methodology will improve the diagnosis and therapy during the process of decision making. Experts from CEE countries recognized the potential of artificial intelligence-based methods employing real-world data for diabetes modelling. These methods are seen as instrumental in elucidating the heterogeneous nature of the disease, supporting clinician decision-making and holding promises for HTA purposes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries

Author

Jakubowski, Szczepan, primary, Kawalec, Pawel, additional, Holko, Przemyslaw, additional, Kowalska-Bobko, Iwona, additional, Kamusheva, Maria, additional, Petrova, Guenka, additional, Draganić, Pero, additional, Fuksa, Leos, additional, Männik, Agnes, additional, Ispán, Fanni, additional, Briedis, Vitalis, additional, Bianchi, Ioana, additional, Paveliu, Marian Sorin, additional, and Tesar, Tomas, additional

Published
2024
Full Text
View/download PDF

13. Recommendations for patient involvement in health technology assessment in Central and Eastern European countries

Author

Jakab, Ivett, primary, Dimitrova, Maria, additional, Houÿez, François, additional, Bereczky, Tamás, additional, Fövényes, Miroslava, additional, Maravic, Zorana, additional, Belina, Ivica, additional, Andriciuc, Christian, additional, Tóth, Krisztina, additional, Piniazhko, Oresta, additional, Hren, Rok, additional, Gutierrez-Ibarluzea, Iñaki, additional, Czech, Marcin, additional, Tesar, Tomas, additional, Niewada, Maciej, additional, Lorenzovici, László, additional, Kamusheva, Maria, additional, Manova, Manoela, additional, Savova, Alexandra, additional, Mitkova, Zornitsa, additional, Tachkov, Konstantin, additional, Németh, Bertalan, additional, Petykó, Zsuzsanna Ida, additional, Dawoud, Dalia, additional, Delnoij, Diana, additional, Knies, Saskia, additional, Goettsch, Wim, additional, and Kaló, Zoltán, additional

Published
2023
Full Text
View/download PDF

15. Recommendations for patient involvement in health technology assessment in Central and Eastern European countries

Author

Jakab, Ivett, Dimitrova, Maria, Houyez, Francois, Bereczky, Tamas, Fovenyes, Miroslava, Maravic, Zorana, Belina, Ivica, Andriciuc, Christian, Toth, Krisztina, Piniazhko, Oresta, Hren, Rok, Gutierrez-Ibarluzea, Inaki, Czech, Marcin, Tesar, Tomas, Niewada, Maciej, Lorenzovici, Laszlo, Kamusheva, Maria, Manova, Manoela, Savova, Alexandra, Mitkova, Zornitsa, Tachkov, Konstantin, Nemeth, Bertalan, Petyko, Zsuzsanna Ida, Dawoud, Dalia, Delnoij, Diana, Knies, Saskia, Goettsch, Wim, Kalo, Zoltan, Jakab, Ivett, Dimitrova, Maria, Houyez, Francois, Bereczky, Tamas, Fovenyes, Miroslava, Maravic, Zorana, Belina, Ivica, Andriciuc, Christian, Toth, Krisztina, Piniazhko, Oresta, Hren, Rok, Gutierrez-Ibarluzea, Inaki, Czech, Marcin, Tesar, Tomas, Niewada, Maciej, Lorenzovici, Laszlo, Kamusheva, Maria, Manova, Manoela, Savova, Alexandra, Mitkova, Zornitsa, Tachkov, Konstantin, Nemeth, Bertalan, Petyko, Zsuzsanna Ida, Dawoud, Dalia, Delnoij, Diana, Knies, Saskia, Goettsch, Wim, and Kalo, Zoltan

Abstract

IntroductionMeaningful patient involvement in health technology assessment (HTA) is essential in ensuring that the interests of the affected patient population, their families, and the general public are accurately reflected in coverage and reimbursement decisions. Central and Eastern European (CEE) countries are generally at less advanced stages of implementing HTA, which is particularly true for patient involvement activities. As part of the Horizon2020 HTx project, this research aimed to form recommendations for critical barriers to patient involvement in HTA in CEE countries. MethodsBuilt on previous research findings on potential barriers, a prioritisation survey was conducted online with CEE stakeholders. Recommendations for prioritised barriers were formed through a face-to-face workshop by CEE stakeholders and HTx experts. ResultsA total of 105 stakeholders from 13 CEE countries completed the prioritisation survey and identified 12 of the 22 potential barriers as highly important. The workshop had 36 participants representing 9 CEE countries, and 5 Western European countries coming together to discuss solutions in order to form recommendations based on best practices, real-life experience, and transferability aspects. Stakeholder groups involved in both phases included HTA organisation representatives, payers, patients, caregivers, patient organisation representatives, patient experts, health care providers, academic and non-academic researchers, health care consultants and health technology manufacturers/providers. As a result, 12 recommendations were formed specified to the CEE region's context, but potentially useful for a broader geographic audience. ConclusionIn this paper, we present 12 recommendations for meaningful, systematic, and sustainable patient involvement in HTA in CEE countries. Our hope is that engaging more than a hundred CEE stakeholders in the study helped to spread awareness of the importance and potential of patient involvement and tha

Published
2023

16. Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making

Author

Németh, Bertalan, Kamusheva, Maria, Mitkova, Zornitsa, Petykó, Zsuzsanna Ida, Zemplényi, Antal, Dimitrova, Maria, Tachkov, Konstantin, Balkányi, László, Czech, Marcin, Dawoud, Dalia, Goettsch, Wim, Hren, Rok, Knies, Saskia, Lorenzovici, László, Maravic, Zorana, Piniazhko, Oresta, Zerovnik, Spela, Kaló, Zoltán, Németh, Bertalan, Kamusheva, Maria, Mitkova, Zornitsa, Petykó, Zsuzsanna Ida, Zemplényi, Antal, Dimitrova, Maria, Tachkov, Konstantin, Balkányi, László, Czech, Marcin, Dawoud, Dalia, Goettsch, Wim, Hren, Rok, Knies, Saskia, Lorenzovici, László, Maravic, Zorana, Piniazhko, Oresta, Zerovnik, Spela, and Kaló, Zoltán

Abstract

Aim: Real-world data and real-world evidence (RWE) are becoming more important for healthcare decision making and health technology assessment. We aimed to propose solutions to overcome barriers preventing Central and Eastern European (CEE) countries from using RWE generated in Western Europe. Materials & methods: To achieve this, following a scoping review and a webinar, the most important barriers were selected through a survey. A workshop was held with CEE experts to discuss proposed solutions. Results: Based on survey results, we selected the nine most important barriers. Multiple solutions were proposed, for example, the need for a European consensus, and building trust in using RWE. Conclusion: Through collaboration with regional stakeholders, we proposed a list of solutions to overcome barriers on transferring RWE from Western Europe to CEE countries. Plain language summary: Collecting real-world data and generating real-world evidence from it is becoming more important for making better decisions in healthcare. We investigated the main barriers which prevent using real-world evidence in Central and Eastern Europe, originally generated in Western Europe. After identifying the nine most important barrier, with the help of local experts we proposed solutions to overcome those barriers. Several possible solutions were proposed, many of them highlighting the need for a European consensus on these matters and building trust in new methods. Our results can hopefully serve as a guidance document to help overcome the barriers. Tweetable abstract: Research investigating ways to overcome barriers preventing Central and Eastern European countries from using Western European real-world evidence for healthcare decision making, using a multi-methods approach to create a list of solutions in collaboration with local stakeholders.

Published
2023

17. Burden of infectious disease studies in Europe and the United Kingdom: a review of methodological design choices

Author

UCL - SSS/IRSS - Institut de recherche santé et société, Charalampous, Periklis, Haagsma, Juanita A, Jakobsen, Lea S, Gorasso, Vanessa, Noguer, Isabel, Padron-Monedero, Alicia, Sarmiento, Rodrigo, Santos, João Vasco, McDonald, Scott A, Plass, Dietrich, Wyper, Grant M A, Assunção, Ricardo, von der Lippe, Elena, Ádám, Balázs, AlKerwi, Ala'a, Arabloo, Jalal, Baltazar, Ana Lúcia, Bikbov, Boris, Borrell-Pages, Maria, Brus, Iris, Burazeri, Genc, Chaintoutis, Serafeim C, Chen-Xu, José, Chkhaberidze, Nino, Cilovic-Lagarija, Seila, Corso, Barbara, Cuschieri, Sarah, Di Bari, Carlotta, Dopelt, Keren, Economou, Mary, Emeto, Theophilus I, Fantke, Peter, Fischer, Florian, Freitas, Alberto, García-González, Juan Manuel, Gazzelloni, Federica, Gissler, Mika, Gkitakou, Artemis, Gulmez, Hakan, Gunes, Sezgin, Haller, Sebastian, Haneef, Romana, Hincapié, Cesar A, Hynds, Paul, Idavain, Jane, Ilic, Milena, Ilic, Irena, Isola, Gaetano, Kabir, Zubair, Kamusheva, Maria, Kolkhir, Pavel, Konar, Naime Meriç, Kostoulas, Polychronis, Kulimbet, Mukhtar, La Vecchia, Carlo, Lauriola, Paolo, Levi, Miriam, Majer, Marjeta, Mechili, Enkeleint A, Monasta, Lorenzo, Mondello, Stefania, Muñoz Laguna, Javier, Nena, Evangelia, Ng, Edmond SW, Nguewa, Paul, Niranjan, Vikram, Nola, Iskra Alexandra, O'Caoimh, Rónán, Obradović, Marija, Pallari, Elena, Peyroteo, Mariana, Pinheiro, Vera, Pranjic, Nurka, Reina Ortiz, Miguel, Riva, Silvia, Santoso, Cornelia Melinda Adi, Santric Milicevic, Milena, Schmitt, Tugce, Speybroeck, Niko, Sprügel, Maximilian, Steiropoulos, Paschalis, Stevanovic, Aleksandar, Thygesen, Lau Caspar, Tozija, Fimka, Unim, Brigid, Bektaş Uysal, Hilal, Varga, Orsolya, Vasic, Milena, Vieira, Rafael José, Yigit, Vahit, Devleesschauwer, Brecht, Pires, Sara M, UCL - SSS/IRSS - Institut de recherche santé et société, Charalampous, Periklis, Haagsma, Juanita A, Jakobsen, Lea S, Gorasso, Vanessa, Noguer, Isabel, Padron-Monedero, Alicia, Sarmiento, Rodrigo, Santos, João Vasco, McDonald, Scott A, Plass, Dietrich, Wyper, Grant M A, Assunção, Ricardo, von der Lippe, Elena, Ádám, Balázs, AlKerwi, Ala'a, Arabloo, Jalal, Baltazar, Ana Lúcia, Bikbov, Boris, Borrell-Pages, Maria, Brus, Iris, Burazeri, Genc, Chaintoutis, Serafeim C, Chen-Xu, José, Chkhaberidze, Nino, Cilovic-Lagarija, Seila, Corso, Barbara, Cuschieri, Sarah, Di Bari, Carlotta, Dopelt, Keren, Economou, Mary, Emeto, Theophilus I, Fantke, Peter, Fischer, Florian, Freitas, Alberto, García-González, Juan Manuel, Gazzelloni, Federica, Gissler, Mika, Gkitakou, Artemis, Gulmez, Hakan, Gunes, Sezgin, Haller, Sebastian, Haneef, Romana, Hincapié, Cesar A, Hynds, Paul, Idavain, Jane, Ilic, Milena, Ilic, Irena, Isola, Gaetano, Kabir, Zubair, Kamusheva, Maria, Kolkhir, Pavel, Konar, Naime Meriç, Kostoulas, Polychronis, Kulimbet, Mukhtar, La Vecchia, Carlo, Lauriola, Paolo, Levi, Miriam, Majer, Marjeta, Mechili, Enkeleint A, Monasta, Lorenzo, Mondello, Stefania, Muñoz Laguna, Javier, Nena, Evangelia, Ng, Edmond SW, Nguewa, Paul, Niranjan, Vikram, Nola, Iskra Alexandra, O'Caoimh, Rónán, Obradović, Marija, Pallari, Elena, Peyroteo, Mariana, Pinheiro, Vera, Pranjic, Nurka, Reina Ortiz, Miguel, Riva, Silvia, Santoso, Cornelia Melinda Adi, Santric Milicevic, Milena, Schmitt, Tugce, Speybroeck, Niko, Sprügel, Maximilian, Steiropoulos, Paschalis, Stevanovic, Aleksandar, Thygesen, Lau Caspar, Tozija, Fimka, Unim, Brigid, Bektaş Uysal, Hilal, Varga, Orsolya, Vasic, Milena, Vieira, Rafael José, Yigit, Vahit, Devleesschauwer, Brecht, and Pires, Sara M

Published
2023

18. Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Németh, Bertalan, Kamusheva, Maria, Mitkova, Zornitsa, Petykó, Zsuzsanna Ida, Zemplényi, Antal, Dimitrova, Maria, Tachkov, Konstantin, Balkányi, László, Czech, Marcin, Dawoud, Dalia, Goettsch, Wim, Hren, Rok, Knies, Saskia, Lorenzovici, László, Maravic, Zorana, Piniazhko, Oresta, Zerovnik, Spela, Kaló, Zoltán, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Németh, Bertalan, Kamusheva, Maria, Mitkova, Zornitsa, Petykó, Zsuzsanna Ida, Zemplényi, Antal, Dimitrova, Maria, Tachkov, Konstantin, Balkányi, László, Czech, Marcin, Dawoud, Dalia, Goettsch, Wim, Hren, Rok, Knies, Saskia, Lorenzovici, László, Maravic, Zorana, Piniazhko, Oresta, Zerovnik, Spela, and Kaló, Zoltán

Published
2023

19. Recommendations for patient involvement in health technology assessment in Central and Eastern European countries

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Jakab, Ivett, Dimitrova, Maria, Houyez, Francois, Bereczky, Tamas, Fovenyes, Miroslava, Maravic, Zorana, Belina, Ivica, Andriciuc, Christian, Toth, Krisztina, Piniazhko, Oresta, Hren, Rok, Gutierrez-Ibarluzea, Inaki, Czech, Marcin, Tesar, Tomas, Niewada, Maciej, Lorenzovici, Laszlo, Kamusheva, Maria, Manova, Manoela, Savova, Alexandra, Mitkova, Zornitsa, Tachkov, Konstantin, Nemeth, Bertalan, Petyko, Zsuzsanna Ida, Dawoud, Dalia, Delnoij, Diana, Knies, Saskia, Goettsch, Wim, Kalo, Zoltan, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, PECP - Centre for Pharmaceutical Policy and Regulation, Jakab, Ivett, Dimitrova, Maria, Houyez, Francois, Bereczky, Tamas, Fovenyes, Miroslava, Maravic, Zorana, Belina, Ivica, Andriciuc, Christian, Toth, Krisztina, Piniazhko, Oresta, Hren, Rok, Gutierrez-Ibarluzea, Inaki, Czech, Marcin, Tesar, Tomas, Niewada, Maciej, Lorenzovici, Laszlo, Kamusheva, Maria, Manova, Manoela, Savova, Alexandra, Mitkova, Zornitsa, Tachkov, Konstantin, Nemeth, Bertalan, Petyko, Zsuzsanna Ida, Dawoud, Dalia, Delnoij, Diana, Knies, Saskia, Goettsch, Wim, and Kalo, Zoltan

Published
2023

20. Burden of infectious disease studies in Europe and the United Kingdom:a review of methodological design choices

Author

Charalampous, Periklis, Haagsma, Juanita A., Jakobsen, Lea S., Gorasso, Vanessa, Noguer, Isabel, Padron-Monedero, Alicia, Sarmiento, Rodrigo, Santos, João Vasco, Mcdonald, Scott A., Plass, Dietrich, Wyper, Grant M.A., Assunção, Ricardo, Von Der Lippe, Elena, Ádám, Balázs, Alkerwi, Ala'a, Arabloo, Jalal, Baltazar, Ana Lúcia, Bikbov, Boris, Borrell-Pages, Maria, Brus, Iris, Burazeri, Genc, Chaintoutis, Serafeim C., Chen-Xu, José, Chkhaberidze, Nino, Cilovic-Lagarija, Seila, Corso, Barbara, Cuschieri, Sarah, Di Bari, Carlotta, Dopelt, Keren, Economou, Mary, Emeto, Theophilus I., Fantke, Peter, Fischer, Florian, Freitas, Alberto, García-González, Juan Manuel, Gazzelloni, Federica, Gissler, Mika, Gkitakou, Artemis, Gulmez, Hakan, Gunes, Sezgin, Haller, Sebastian, Haneef, Romana, Hincapié, Cesar A., Hynds, Paul, Idavain, Jane, Ilic, Milena, Ilic, Irena, Isola, Gaetano, Kabir, Zubair, Kamusheva, Maria, Kolkhir, Pavel, Konar, Naime Meriç, Kostoulas, Polychronis, Kulimbet, Mukhtar, La Vecchia, Carlo, Lauriola, Paolo, Levi, Miriam, Majer, Marjeta, Mechili, Enkeleint A., Monasta, Lorenzo, Mondello, Stefania, Muñoz Laguna, Javier, Nena, Evangelia, Ng, Edmond S.W., Nguewa, Paul, Niranjan, Vikram, Nola, Iskra Alexandra, O'caoimh, Rónán, Obradović, Marija, Pallari, Elena, Peyroteo, Mariana, Pinheiro, Vera, Pranjic, Nurka, Reina Ortiz, Miguel, Riva, Silvia, Santoso, Cornelia Melinda Adi, Santric Milicevic, Milena, Schmitt, Tugce, Speybroeck, Niko, Sprügel, Maximilian, Steiropoulos, Paschalis, Stevanovic, Aleksandar, Thygesen, Lau Caspar, Tozija, Fimka, Unim, Brigid, Bektaş Uysal, Hilal, Varga, Orsolya, Vasic, Milena, Vieira, Rafael José, Yigit, Vahit, Devleesschauwer, Brecht, Pires, Sara M., Charalampous, Periklis, Haagsma, Juanita A., Jakobsen, Lea S., Gorasso, Vanessa, Noguer, Isabel, Padron-Monedero, Alicia, Sarmiento, Rodrigo, Santos, João Vasco, Mcdonald, Scott A., Plass, Dietrich, Wyper, Grant M.A., Assunção, Ricardo, Von Der Lippe, Elena, Ádám, Balázs, Alkerwi, Ala'a, Arabloo, Jalal, Baltazar, Ana Lúcia, Bikbov, Boris, Borrell-Pages, Maria, Brus, Iris, Burazeri, Genc, Chaintoutis, Serafeim C., Chen-Xu, José, Chkhaberidze, Nino, Cilovic-Lagarija, Seila, Corso, Barbara, Cuschieri, Sarah, Di Bari, Carlotta, Dopelt, Keren, Economou, Mary, Emeto, Theophilus I., Fantke, Peter, Fischer, Florian, Freitas, Alberto, García-González, Juan Manuel, Gazzelloni, Federica, Gissler, Mika, Gkitakou, Artemis, Gulmez, Hakan, Gunes, Sezgin, Haller, Sebastian, Haneef, Romana, Hincapié, Cesar A., Hynds, Paul, Idavain, Jane, Ilic, Milena, Ilic, Irena, Isola, Gaetano, Kabir, Zubair, Kamusheva, Maria, Kolkhir, Pavel, Konar, Naime Meriç, Kostoulas, Polychronis, Kulimbet, Mukhtar, La Vecchia, Carlo, Lauriola, Paolo, Levi, Miriam, Majer, Marjeta, Mechili, Enkeleint A., Monasta, Lorenzo, Mondello, Stefania, Muñoz Laguna, Javier, Nena, Evangelia, Ng, Edmond S.W., Nguewa, Paul, Niranjan, Vikram, Nola, Iskra Alexandra, O'caoimh, Rónán, Obradović, Marija, Pallari, Elena, Peyroteo, Mariana, Pinheiro, Vera, Pranjic, Nurka, Reina Ortiz, Miguel, Riva, Silvia, Santoso, Cornelia Melinda Adi, Santric Milicevic, Milena, Schmitt, Tugce, Speybroeck, Niko, Sprügel, Maximilian, Steiropoulos, Paschalis, Stevanovic, Aleksandar, Thygesen, Lau Caspar, Tozija, Fimka, Unim, Brigid, Bektaş Uysal, Hilal, Varga, Orsolya, Vasic, Milena, Vieira, Rafael José, Yigit, Vahit, Devleesschauwer, Brecht, and Pires, Sara M.

Abstract

This systematic literature review aimed to provide an overview of the characteristics and methods used in studies applying the Disability-Adjusted Life Years (DALY) concept for infectious diseases within European Union (EU)/European Economic Area (EEA)/European Free Trade Association (EFTA) countries and the United Kingdom. Electronic databases and grey literature were searched for articles reporting the assessment of DALY and its components. We considered studies in which researchers performed DALY calculations using primary epidemiological data input sources. We screened 3,053 studies of which 2,948 were excluded and 105 studies met our inclusion criteria. Of these studies, 22 were multi-country and 83 were single-country studies, of which 46 were from the Netherlands. Food- and water-borne diseases were the most frequently studied infectious diseases. Between 2015 and 2022, the number of burden of infectious disease studies was 1.6 times higher compared to that published between 2000 and 2014. Almost all studies (97%) estimated DALYs based on the incidence- and pathogen-based approach and without social weighting functions; however, there was less methodological consensus with regards to the disability weights and life tables that were applied. The number of burden of infectious disease studies undertaken across Europe has increased over time. Development and use of guidelines will promote performing burden of infectious disease studies and facilitate comparability of the results.

Published
2023

22. COST-EFFECTIVENESS OF DISEASE-MODIFYING TREATMENTS FOR MULTIPLE SCLEROSIS IN BULGARIA BASED ON EVIDENCE FROM REAL WORLD SETTINGS.

Author

DIMITROVA, MARIA, SEITARIDOU, YOANA, LAZAROVA, RUMYANA, PETROVA, GUENKA, MITOV, KONSTANTIN, MILANOV, IVAN, MARINOV, LYUBOMIR, KAMUSHEVA, MARIA, and PANAYOTOV, PAVEL

Subjects
MULTIPLE sclerosis, COST effectiveness, MEDICAL care costs, GROSS domestic product
Abstract

Copyright of Farmacia is the property of Societatea de Stiinte Farmaceutice Romania and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

24. Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making

Author

Németh, Bertalan, primary, Kamusheva, Maria, additional, Mitkova, Zornitsa, additional, Petykó, Zsuzsanna Ida, additional, Zemplényi, Antal, additional, Dimitrova, Maria, additional, Tachkov, Konstantin, additional, Balkányi, László, additional, Czech, Marcin, additional, Dawoud, Dalia, additional, Goettsch, Wim, additional, Hren, Rok, additional, Knies, Saskia, additional, Lorenzovici, László, additional, Maravic, Zorana, additional, Piniazhko, Oresta, additional, Zerovnik, Spela, additional, and Kaló, Zoltán, additional

Published
2023
Full Text
View/download PDF

26. Methodological Quality of Retrospective Observational Studies Investigating Effects of Diabetes Monitoring Systems: a Systematic Review

Author

Jiu, Li, primary, Wang, Junfeng, additional, Kamusheva, Maria, additional, Dimitrova, Maria, additional, Tachkov, Konstantin, additional, Milushewa, Petya, additional, Mitkova, Zornitsa, additional, Petrova, Guenka, additional, Vreman, Rick, additional, Mantel-Teeuwisse, Aukje K., additional, and Goettsch, Wim, additional

Published
2023
Full Text
View/download PDF

27. Burden of infectious disease studies in Europe and the United Kingdom: a review of methodological design choices

Author

Charalampous, Periklis, primary, Haagsma, Juanita A., additional, Jakobsen, Lea S., additional, Gorasso, Vanessa, additional, Noguer, Isabel, additional, Padron-Monedero, Alicia, additional, Sarmiento, Rodrigo, additional, Santos, João Vasco, additional, McDonald, Scott A., additional, Plass, Dietrich, additional, Wyper, Grant M. A., additional, Assunção, Ricardo, additional, von der Lippe, Elena, additional, Ádám, Balázs, additional, AlKerwi, Ala'a, additional, Arabloo, Jalal, additional, Baltazar, Ana Lúcia, additional, Bikbov, Boris, additional, Borrell-Pages, Maria, additional, Brus, Iris, additional, Burazeri, Genc, additional, Chaintoutis, Serafeim C., additional, Chen-Xu, José, additional, Chkhaberidze, Nino, additional, Cilovic-Lagarija, Seila, additional, Corso, Barbara, additional, Cuschieri, Sarah, additional, Di Bari, Carlotta, additional, Dopelt, Keren, additional, Economou, Mary, additional, Emeto, Theophilus I., additional, Fantke, Peter, additional, Fischer, Florian, additional, Freitas, Alberto, additional, García-González, Juan Manuel, additional, Gazzelloni, Federica, additional, Gissler, Mika, additional, Gkitakou, Artemis, additional, Gulmez, Hakan, additional, Gunes, Sezgin, additional, Haller, Sebastian, additional, Haneef, Romana, additional, Hincapié, Cesar A., additional, Hynds, Paul, additional, Idavain, Jane, additional, Ilic, Milena, additional, Ilic, Irena, additional, Isola, Gaetano, additional, Kabir, Zubair, additional, Kamusheva, Maria, additional, Kolkhir, Pavel, additional, Konar, Naime Meriç, additional, Kostoulas, Polychronis, additional, Kulimbet, Mukhtar, additional, La Vecchia, Carlo, additional, Lauriola, Paolo, additional, Levi, Miriam, additional, Majer, Marjeta, additional, Mechili, Enkeleint A., additional, Monasta, Lorenzo, additional, Mondello, Stefania, additional, Muñoz Laguna, Javier, additional, Nena, Evangelia, additional, Ng, Edmond S. W., additional, Nguewa, Paul, additional, Niranjan, Vikram, additional, Nola, Iskra Alexandra, additional, O'Caoimh, Rónán, additional, Obradović, Marija, additional, Pallari, Elena, additional, Peyroteo, Mariana, additional, Pinheiro, Vera, additional, Pranjic, Nurka, additional, Reina Ortiz, Miguel, additional, Riva, Silvia, additional, Santoso, Cornelia Melinda Adi, additional, Santric Milicevic, Milena, additional, Schmitt, Tugce, additional, Speybroeck, Niko, additional, Sprügel, Maximilian, additional, Steiropoulos, Paschalis, additional, Stevanovic, Aleksandar, additional, Thygesen, Lau Caspar, additional, Tozija, Fimka, additional, Unim, Brigid, additional, Bektaş Uysal, Hilal, additional, Varga, Orsolya, additional, Vasic, Milena, additional, Vieira, Rafael José, additional, Yigit, Vahit, additional, Devleesschauwer, Brecht, additional, and Pires, Sara M., additional

Published
2023
Full Text
View/download PDF

30. Cost-effectiveness of treatment intervention in prediabetic patients in Bulgaria.

Author

Yordanova, Stanislava, Mitov, Konstantin, and Kamusheva, Maria

Subjects
COST effectiveness, COVID-19 pandemic, ANTIBIOTICS, RESPIRATORY infections, DATA analysis
Abstract

Introduction: The study aims to evaluate the cost-effectiveness (CE) of an early intervention in prediabetes (metformin) in order to prevent or slow down the onset of diabetes in those at high risk compared with the current “do nothing” approach. Materials and methods: An Excel-based model was developed. The results of the CE and cost-utility analyses are presented as an ICER (incremental cost-effectiveness ratio) and ICUR (incremental cost-utility ratio), respectively. Markov model of the cost or potential savings from the perspective of the National Health Insurance Fund in Bulgaria was performed. Results: The ICER of the metformin intervention in prediabetes patients compared with “do nothing” routine shows that metformin treatment produced more health benefits (number of prevented diabetes cases) on a lower cost for the public payer. The ICER calculated is -7,122.32 BGN per number of prevented diabetes cases and it confirms cost-savings are possible when metformin is applied compared with the “do nothing” approach. The ICUR per quality-adjusted life years (QALYs) gained also shows the metformin preventive intervention as a dominant and cost-saving alternative. The Markov model simulation confirms the intervention with metformin is less costly in a long-term and leads to higher QALYs. Conclusion: The investment in a preventive intervention with metformin offers an excellent value for money. The ICER of the metformin intervention in prediabetes patients compared with “do nothing” routine shows that metformin preventive intervention produced more health benefits on a lower cost for the public payer in Bulgaria. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. The European challenges of funding orphan medicinal products

Author

Szegedi, Márta, Zelei, Tamás, Arickx, Francis, Bucsics, Anna, Cohn-Zanchetta, Emanuelle, Fürst, Jurij, Kamusheva, Maria, Kawalec, Pawel, Petrova, Guenka, Slaby, Juraj, Stawowczyk, Ewa, Vocelka, Milan, Zechmeister-Koss, Ingrid, Kaló, Zoltán, and Molnár, Mária Judit

Published
2018
Full Text
View/download PDF

32. Medication Adherence Enhancing Interventions (MAEI) in patients with non-communicable chronic diseases: a protocol of systematic review and meta-analysis

Author

Treciokiene, Indre, Hafez, Gaye, Mala-Ladova, Katerina, Bago, Martina, Fernandez, Francisca, Kamusheva, Maria, Duborija-Kovacevic, Natasa, Smilkov, Katarina, Rogue, Fatima, SFAKIANAKIS, MICHAIL, Ioannidou, Elena, Tittmann, Judit, Drakul, Dragana, Qvarnstrom, Miriam, Cakmak, Seher, de Sousa, Jaime, Cretu, Aurelia, and Potocnjak, Ines

Subjects
Health and Medical Administration, Medicine and Health Sciences, Other Pharmacy and Pharmaceutical Sciences, Pharmacy and Pharmaceutical Sciences, Other Medicine and Health Sciences
Abstract

This is a protocol for systematic review and meta analysis. The objectives of this study are to identify which medication adherence enhancing interventions are effective in chronic health conditions and which of the methods are used to assess medication adherence in those studies. Additionally, facilitators and barriers in medication adherence enhancing interventions will be identified.

Published
2022
Full Text
View/download PDF

37. Quality of life, control of treatment and satisfaction of patients with asthma in Bulgaria: a pilot study

Author

Doneva, Miglena, Doneva, Miglena, Milushewa, Petya, Dimitrova, Maria, Kamusheva, Maria, Stoitchkov, Jordan, Petrova, Guenka, Naydenova, Kremena, Krusheva, Borislava, Dimitrov, Vasil, Lakić, Dragana, Doneva, Miglena, Doneva, Miglena, Milushewa, Petya, Dimitrova, Maria, Kamusheva, Maria, Stoitchkov, Jordan, Petrova, Guenka, Naydenova, Kremena, Krusheva, Borislava, Dimitrov, Vasil, and Lakić, Dragana

Abstract

This study aims to evaluate clinical characteristics, quality of life and control of treatment and therapy satisfaction of patients with asthma in Bulgaria. A pilot study of Bulgarian patients with asthma selected by allergologists was performed. The predefined inclusion criteria were asthma diagnosis with at least 6 months of living with asthma and use of asthma medication. Patient characteristics, treatment, quality-of-life, control of asthma and therapy satisfaction were systematically assessed. A retrospective observational study was conducted among asthma patients in Sofia in 2019. A strict definition of asthma-based solely on physicians’ diagnosis was used. Allergologists from two national reference hospitals for asthma therapy selected asthma patients. Every third patient with asthma that visited the office within 5 months period, and that agreed to participate was selected for the study. Quality-of-life of patients was measured using the EQ5D Assessment Test, control of asthma was assessed using ATCQ and ATC tests. A total of 71 asthma patients were enrolled. Approximately 43.6% were male, 16.9% were smokers, occupational risk factors were low (4.22%), 25% had moderate and 38% had severe asthma. The mean scores of asthma control treatment were 16.92 ± 5.68. The group has relatively high percentages of severe asthma patients. The asthma was not well controlled. National asthma strategies should focus on prevention and early detection of the disease.

Published
2022

38. Potential Barriers of Patient Involvement in Health Technology Assessment in Central and Eastern European Countries

Author

Dimitrova, Maria, Jakab, Ivett, Mitkova, Zornitsa, Kamusheva, Maria, Tachkov, Konstantin, Nemeth, Bertalan, Zemplenyi, Antal, Dawoud, Dalia, Delnoij, Diana M.J., Houýez, François, Kalo, Zoltan, Dimitrova, Maria, Jakab, Ivett, Mitkova, Zornitsa, Kamusheva, Maria, Tachkov, Konstantin, Nemeth, Bertalan, Zemplenyi, Antal, Dawoud, Dalia, Delnoij, Diana M.J., Houýez, François, and Kalo, Zoltan

Abstract

Patients' perspectives are important to identify preferences, estimate values and appreciate unmet medical needs in the process of research and development and subsequent assessment of new health technologies. Patient and public involvement in health technology assessment (HTA) is essential in understanding and assessing wider implications of coverage and reimbursement decisions for patients, their relatives, caregivers, and the general population. There are two approaches to incorporating the patients' voice in HTA, preferably used in a mix. In the first one, patients, caregivers and/or their representatives directly participate at discussions in different stages of the HTA process, often at the same table with other stakeholders. Secondly, patient involvement activities can be supported by evidence on patient value and experience collected directly from patients, caregivers and/or their representatives often by patient groups Patient involvement practices, however, are limited in Central and Eastern European (CEE) countries without clear methodology or regulatory mechanisms to guide patient involvement in the HTA process. This poses the question of transferability of practices used in other countries, and might call for the development of new CEE-specific guidelines and methods. In this study we aim to map potential barriers of patient involvement in HTA in countries of the CEE region.

Published
2022

40. The Potential Role of the Pharmacist in Supporting Patients with Depression – A Literature-Based Point of View

Author

Kamusheva, Maria, Ignatova, Desislava, Golda, Anna, and Skowron, Agnieszka

Subjects
depression, pharmaceutical care, pharmacists, Review, guideline, drug-related problems
Abstract

Objective The current article is aimed at identifying the best practice for counseling around depression in community and outpatient pharmacies, resulting in a draft guideline, proposing key steps and an algorithm for integration of community pharmacists into care for patients with depression. Methods A literature review was performed followed by a detailed analysis, for the purpose of creation a short draft document used as a basis for creation of a guideline for pharmaceutical care for patients with depression. The technological scheme PRISMA flow diagram was applied. The paper is based on current knowledge, taking into consideration already published articles, guidelines, and recommendations about pharmaceutical care for patients with depression, giving a basis for further studies. Results This paper includes two main sections: 1) depression – a short description of the main symptoms, risk factors and pharmacotherapy guidelines available in Bulgaria important for the purposes of ensuring qualitative community-based pharmaceutical care; and 2) the pharmacists’ role in providing high-quality care – the main aspects of pharmaceutical care for patients with depression with specific examples. Conclusion The involvement of pharmacists in supporting depressive patients is crucial taking into account the specific characteristics of the pharmacological treatment: delayed onset of clinical results, risks in case of sudden pharmacotherapy abruption without physician consultation, multiple adverse drug reactions and drug–drug, drug–food and drug–alcohol interactions, etc. The current article could also be used as an initial document for creating a methodological guideline for providing pharmaceutical care services for patients with depression.

Published
2020

45. Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries

Author

Turcu-Stiolica, Adina, primary, Kamusheva, Maria, additional, Bogdan, Maria, additional, Tadic, Ivana, additional, Harasani, Klejda, additional, Subtirelu, Mihaela-Simona, additional, Meca, Andreea-Daniela, additional, Šesto, Sofia, additional, Odalović, Marina, additional, Arsić, Jasmina, additional, Stojkov, Svetlana, additional, Terzieva, Emili, additional, and Petrova, Guenka, additional

Published
2021
Full Text
View/download PDF

49. Figure 1 from: Ivanova V, Pavlov D, Assenova T, Terzieva E, Milushewa P, Djemadan A, Vladimirova G, Dimitrova M, Kamusheva M (2021) COVID-19 pandemic impact on the pharmaceutical sector in Bulgaria. Pharmacia 68(3): 713-720. https://doi.org/10.3897/pharmacia.68.e71638

Author

Ivanova, Veselina, primary, Pavlov, Deyan, additional, Assenova, Tolya, additional, Terzieva, Emily, additional, Milushewa, Petya, additional, Djemadan, Alime, additional, Vladimirova, Gergana, additional, Dimitrova, Maria, additional, and Kamusheva, Maria, additional

Published
2021
Full Text
View/download PDF

50. Figure 3 from: Ivanova V, Pavlov D, Assenova T, Terzieva E, Milushewa P, Djemadan A, Vladimirova G, Dimitrova M, Kamusheva M (2021) COVID-19 pandemic impact on the pharmaceutical sector in Bulgaria. Pharmacia 68(3): 713-720. https://doi.org/10.3897/pharmacia.68.e71638

Author

Ivanova, Veselina, primary, Pavlov, Deyan, additional, Assenova, Tolya, additional, Terzieva, Emily, additional, Milushewa, Petya, additional, Djemadan, Alime, additional, Vladimirova, Gergana, additional, Dimitrova, Maria, additional, and Kamusheva, Maria, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results